<DOC>
	<DOCNO>NCT01858389</DOCNO>
	<brief_summary>This Phase 2 study oral dacomitinib give every 12 hour day 1-4 two-week cycle patient Non-small cell lung cancer . The study include two group patient , whose tumor document T790M mutation , without mutation . All patient receive repeat cycle dacomitinib disease progression , occurrence unacceptable toxicity , withdrawal criterion meet .</brief_summary>
	<brief_title>A Study Of Dacomitinib ( PF-00299804 ) In Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Evidence histologically confirm , advance NSCLC ( stage IIIB/IV ) . Evidence T790M mutation enroll Cohort A . Evidence measurable disease radiographic technique . Adequate organ function . Patients T790M mutation stop prior EGFRdirected therapy without evidence disease progression . Symptomatic brain metastasis . Uncontrolled significant cardiovascular disease . Pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>T790M mutation . dacomitinib</keyword>
</DOC>